Latest news with #MA-based
Yahoo
2 days ago
- Business
- Yahoo
Why PTC Inc. (PTC) is a Top Value Stock for the Long-Term
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum. Different than growth or momentum investors, value-focused investors are all about finding good stocks at good prices, and discovering which companies are trading under what their true value is before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks. Boston, MA-based PTC Inc is a software provider offering a range of cutting-edge digital technologies that collectively revolutionize the engineering, production, and maintenance of tangible goods. Founded in 1985, the company was formerly known as Parametric Technology Corporation and changed its name to PTC Inc in January 2013. PTC sits at a Zacks Rank #3 (Hold), holds a Value Style Score of B, and has a VGM Score of A. Compared to the Computer - Software industry's P/E of 27.8X, shares of PTC Inc. are trading at a forward P/E of 27.8X. PTC also has a PEG Ratio of 1.8, a Price/Cash Flow ratio of 34.6X, and a Price/Sales ratio of 8.6X. Many value investors pay close attention to a company's earnings as well. For PTC, six analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.25 to $6.03 per share for 2025. Per share PTC boasts an average earnings surprise of 14.6%. Investors should take the time to consider PTC for their portfolios due to its solid Zacks Ranks, notable earnings and valuation metrics, and impressive Value and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PTC Inc. (PTC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
28-05-2025
- Business
- Yahoo
Why Waters (WAT) is a Top Growth Stock for the Long-Term
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term. For growth investors, a company's financial strength, overall health, and future outlook take precedence, so they'll want to zero in on the Growth Style Score. This Score examines things like projected and historical earnings, sales, and cash flow to find stocks that will generate sustainable growth over time. Milford, MA-based, Waters Corp. is an analytical instrument manufacturer and offers practical and sustainable products for laboratory-dependent organizations. Moreover, Waters provides analytical workflow solutions based on mass spectrometry (MS), liquid chromatography (LC) and thermal analysis technologies. WAT boasts a Growth Style Score of A and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Its bottom-line is projected to rise 8.7% year-over-year for 2025, while Wall Street anticipates its top line to improve by 5.1%. Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2025. The Zacks Consensus Estimate has increased $0.01 to $12.89 per share. WAT boasts an average earnings surprise of 4%. Looking at cash flow, Waters is expected to report cash flow growth of 4.1% this year; WAT has generated cash flow growth of 4.6% over the past three to five years. Investors should take the time to consider WAT for their portfolios due to its solid Zacks Rank rating, notable growth metrics, and impressive Growth and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Waters Corporation (WAT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
27-05-2025
- Business
- Yahoo
HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick?
With women's health increasingly becoming a global priority, investors are actively targeting companies operating in this space to boost their portfolios. Research and Markets projects the women's health diagnostics market to expand at a compound annual rate of 9.25% through 2030, driven by technological advancements, increasing healthcare expenditures, and initiatives for early detection of women-specific conditions like reproductive health issues, breast cancer, osteoporosis and more. Two U.S. healthcare innovators, Hologic HOLX and Quest Diagnostics DGX, have established a strong foothold in this space, each with its own areas of specialization. Hologic, with a market cap of $12.10 billion, develops products and services across the women's healthcare continuum, such as advanced diagnostics products, medical imaging systems and surgical products. In comparison, Quest Diagnostics, with a market cap of $19.12 billion, provides a comprehensive portfolio of diagnostic tests for all stages of a woman's life — from routine screenings like cervical cancer and sexually transmitted infections (STIs) to pregnancy and fertility testing. Between these two, which one stands out as the smarter pick now? Let's dive deep into their fundamentals, growth drivers and challenges to find out. The Marlborough, MA-based company benefits from its strategy of building multiple durable growth drivers across all its global franchises. Key offerings include Aptima and Panther Fusion assays for sexually transmitted diseases (STDs), vaginitis and respiratory infections. The BV/CV/TV assay shows strong double-digit growth, supported by rising awareness and reimbursement in the U.S. vaginitis market. Molecular growth is further backed by the Biotheranostics business, driven by the rising adoption of the Breast Cancer Index test. However, weaker HIV testing in Africa due to federal funding cuts affected the fiscal 2025 second-quarter performance and is likely to persist. Hologic is seeing strong adoption of the Genius Digital Diagnostics System — the first FDA-cleared digital cytology system for cervical cancer screening, combining novel artificial intelligence (AI) with advanced imaging. However, Q2 International cytology and perinatal sales were impacted by South Korea's physician strike and reduced hospital spending in China. On the MedTech side, the company's mammography products continue to command leading market shares. In the second quarter, recurring service revenues (more than 45% of total Breast Health revenues) rose 12% year over year. The addition of Endomagnetics enhanced its Interventional Breast portfolio, with Hologic now selling its products directly through its U.S. salesforce to tap into wireless localization market opportunities. However, as anticipated, softer capital equipment sales caused the segment's revenues to decline 7.4%. Internationally, the Surgical business continues to be a standout. The company demonstrates sound financial health, with the flexibility to execute both tuck-in M&A and share repurchases. Still, macroeconomic challenges, including the ongoing trade war in China, have affected its 2025 outlook. Tariffs are expected to impact manufacturing costs by $20 million to $25 million per quarter, with two-thirds of it tied to imports from Costa Rica. Based in Secaucus, NJ, Quest Diagnostics is experiencing strong growth in Women's and Reproductive Health, one of its five key clinical areas where it offers Advanced Diagnostics. The growth is largely driven by prenatal and hereditary genetic testing over the past several quarters. In March 2025, the company launched a new solution that allows patients to self-collect a specimen for human papillomavirus (HPV) cervical cancer screening in a physician's office or other healthcare setting. The test uses Roche's RHHBY HPV self-collection solution and builds on Quest Diagnostics' STI-related self-collection option, introduced in October last year. Other clinical areas — advanced cardiometabolic, autoimmune, brain health and oncology — also posted double-digit growth in the first quarter of 2025, contributing to the 12% year-over-year revenue increase. Recent introductions include a laboratory-developed test to confirm Alzheimer's disease (AD) pathology in symptomatic patients and the Haystack MRD — its first circulating tumor DNA (ctDNA) minimal residual disease (MRD) test for assessing early risk of cancer recurrence. The company continues expanding the Advanced Diagnostics portfolio to enable growth across its core channels: Physicians, Hospitals and Consumers. In 2024, Quest Diagnostics completed eight acquisitions, including LifeLabs in Canada, and formed new health plan relationships. These favorably impacted both Q1 Diagnostic Information Services sales and adjusted operating income, translating to 8.3% growth in adjusted earnings per share (EPS). The company also became the first independent lab in the Optum Health preferred network. In February, Quest Diagnostics extended its chronic kidney disease test portfolio to include dialysis-related laboratory and water testing capabilities via a new agreement with Fresenius Medical Care FMS. Operationally, Quest Diagnostics is increasing the use of automation, robotics and AI across the business to drive productivity gains and improve user experience. The company teamed up with Google Cloud to streamline data management using generative AI. Despite broader economic pressures, Quest Diagnostics reaffirmed its 2025 revenue and adjusted EPS guidance. Yet, its escalating debt levels are a concern, ending the first quarter with $5.86 billion in long-term debt and just $188 million in cash and cash equivalents. The Zacks Consensus Estimate for Hologic's fiscal 2025 sales and EPS implies a year-over-year improvement of 1.2% and 3.2%, respectively. The bottom-line estimates have shown mixed movements in the last 30 days. (See the Zacks Earnings Calendar to stay ahead of market-making news.) Image Source: Zacks Investment Research The Zacks Consensus Estimate for DGX's 2025 sales and EPS suggests a year-over-year improvement of 9.2% and 8.6%, respectively. Analysts seem more bullish on Quest Diagnostics, given the upward EPS estimate revisions in the last 30 days. Image Source: Zacks Investment Research In the past six months, Hologic's shares have plunged significantly, down 31.6%, while the benchmark S&P 500 slipped just 3.2%. In contrast, Quest Diagnostics held its ground with a 4.9% gain. Image Source: Zacks Investment Research Hologic is trading at a forward price-to-sales (P/S) multiple of 2.87X, higher than Quest Diagnostics' 1.75X P/S over the last five years. However, both HOLX and DGX appear discounted when compared to their respective industry averages of 4.04X and 2.71X. Each of them has a Value score of B. Image Source: Zacks Investment Research As a pure-play in women's health, Hologic continues to benefit from its diversified revenue model and growth drivers. International prospects are encouraging, while expanding into new areas through M&A activities instills optimism. While near-term headwinds from both internal and external pressures remain, the company's financial strength and a P/S below the industry suggest potential for long-term stability. For now, holding onto HOLX stock seems like a prudent choice. Meanwhile, Quest Diagnostics, as a clinical laboratory services company, sees strong growth opportunities in the women's and reproductive health space. Steady growth from Advanced Diagnostics and contributions from recent acquisitions are highly promising. Further, the stock's recent favorable performance, attractive valuation and upward analyst estimate revisions make it an equally compelling case to stay invested. HOLX and DGX each carry a Zacks Rank #3 (Hold) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
15-05-2025
- Business
- Associated Press
Mondy Friend Capital Offers Faster, Collateral-Free Alternatives to Traditional Loans
Mondy Friend Capital provides collateral-free credit conversion, serving over 2,500 businesses with AI-driven risk tools. Their model delivers capital in 48 hours, achieving an 82 percent client retention rate and BBB accreditation while targeting blockchain integration by late 2025. Winchester, Massachusetts, United States, May 15, 2025 -- Mondy Friend Capital (MFC), a fintech firm specializing in credit conversion services, now provides startups and small businesses with immediate working capital by converting existing credit lines into liquid funds—no collateral or lengthy approvals required. The BBB-accredited company has facilitated over $75 million in capital for 2,500+ clients since 2023, maintaining an 82 percent repeat client rate and a 4.9/5 TrustPilot score. This announcement comes amid tightening lending conditions, with the Federal Reserve reporting a 15% year-over-year decline in small business loan approval rates at large banks. MFC's model addresses this gap by enabling companies to unlock capital from unused credit limits, bypassing traditional loan requirements. Market Context and Service Differentiation MFC's credit conversion process transforms high-limit credit cards into upfront capital in as quick as 48 hours, avoiding interest accrual and equity dilution. The service targets industries like e-commerce, real estate and marketing agencies, where rapid liquidity is critical for inventory scaling or ad budget expansions. Key features include: Leadership Commentary and Client Impact 'Traditional lenders often leave viable businesses stranded during growth phases,' said Brittany Farley, MFC's Communications Director. 'Our model turns dormant credit into actionable capital, empowering clients to seize opportunities without sacrificing ownership.' A 2024 client case study revealed an e-commerce brand doubled its inventory capacity using converted credit, while a real estate flipper secured $500,000 for a time-sensitive property acquisition. Scalability and Compliance MFC operates with an 11 to 50 member team specializing in compliance and technical implementation. The firm's BBB accreditation since February 2025 underscores its adherence to transparency standards, including public refund policies and client-agreement disclosures. Eligibility requires a minimum $2,000 available credit limit, with no personal guarantees or revenue history mandates. Future Developments MFC plans Q4 2025 blockchain integration for secure cross-border transactions and ESG-aligned credit products for sustainable startups. Emerging markets in Southeast Asia and Latin America are key expansion targets. Visit Mondy Friend Capital to explore credit conversion solutions. About Company/Organization Name Founded in 2023 by industrial systems engineer J. Grey Friend and business management expert Loren Mondy, Mondy Friend Capital provides financial facilitation and business development consulting. The Winchester, MA-based firm combines fintech innovation with Silicon Valley-inspired scalability strategies. Contact Info: Name: Brittany Farley, Director of Communications Email: Send Email Organization: Mondy Friend Capital Website: Release ID: 89160105 If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release that require attention or if there is a need for a press release takedown, we kindly request that you notify us without delay at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or guide you through the removal process. Ensuring accurate and reliable information is fundamental to our mission.
Associated Press
13-02-2025
- Business
- Associated Press
THE GRANITE GROUP OPENS NEWEST BRANCH IN ELLSWORTH, ME
Concord, NH, Feb. 13, 2025 (GLOBE NEWSWIRE) -- The Granite Group, a leading supplier of plumbing, heating, cooling, piping, water systems, and energy products in the Northeast, has announced the opening of its newest branch in Ellsworth, ME. Located at 60 Downeast Highway (Rte. 1), the Ellsworth branch is managed by Derek Foy, a graduate of The Granite Group's Sales & Management Trainee program. Before coming to Ellsworth, Derek worked his way through the company's nearby branch in Bangor, ME, and earned a role helping to lead the inside sales team there. 'Thanks to his experience at our very busy Bangor branch, Derek has an in-depth knowledge of what customers in the area need, and that includes our most important offering: dedication to service. We know Derek and his team will work tirelessly to provide this every day and look forward to seeing them become Ellsworth's new 'go-to' resource for the best products and service in the business,' said Dave Buck, The Granite Group's Senior Director for Northern Branch Sales & Operations. Click here for complete Ellsworth branch details and hours of operation. Including Ellsworth, The Granite Group has added twelve new branches and one new retail showroom over the last year. This expansion includes the acquisition of Springfield, MA-based Premier Supply Group and is part of a strategic plan to bring The Granite Group to areas where customers want them. 'We continue to be deeply committed to growing our footprint in New England, and our approach to that growth has been simple: listen to our customers and our team members. They are as good a compass as you can have for getting a direction on where we need to be next. Between the Premier Supply Group acquisition and the opening of five additional branches in new towns, the last twelve months have been the busiest in the company's history. That said, we have no intention of slowing down and are very excited about the next chapters we will be writing!' said Bill Condron, CEO of The Granite Group. About The Granite Group Headquartered in Concord, NH, The Granite Group distributes plumbing, heating, cooling, piping, water systems, and energy products to contractors and fuel dealers across New England through 68 wholesale branches and a best-in-class online store. The company also operates 17 retail showrooms under the Sink & Spout name, offering an expertly trained staff and an extensive array of bath, kitchen, and lighting products. Founded in 1971 in Worcester, MA, The Granite Group celebrated its 50th anniversary in 2021 alongside the exceptional people who have driven its success. Of all the recognition The Granite Group has received as a business, the workplace awards are the ones for which the company is most proud. For more information, visit
